The MammoScreen Project reached its mid-term milestone last November, and the Consortium took the opportunity to celebrate achievements and identify upcoming challenges. A key highlight of this moment was the elaboration of the first Project Review Report, a comprehensive assessment of the project´s progress, finances, and areas for improvement. Submitted to the tight scrutiny of the European Commission, the report was a great opportunity to ensure that the project remains aligned with its goals and that its stakeholders have an accurate understanding of the progress made in the clinical trial and accompanying activities.
The main conclusion of the Review Report was that significant strides have been made in the previous six months: MammoWave devices were installed in all the testing centers, and the recruitment of clinical trial participants is well on track for the performance checkpoint planned for January 2025. The evaluators also praised the efforts made towards project components such as the MammoScreen App, scientific publications, and dissemination and communication strategies.
In the opinion of our evaluators, MammoScreen has shown remarkable success in promoting an innovative approach to breast health. In their words, the project is a “pioneering effort and an impressive response to the gaps in early breast cancer detection, especially for populations often deterred by traditional mammography due to discomfort or the need for radiation exposure”. In fact, the technology could become particularly relevant for younger women and those with dense breast tissue who may not benefit fully from conventional imaging techniques. Feedback gathered from users so far has highlighted MammoWave as comfortable and easy to use, which is crucial for its long-term adoption.
Overall, the MammoScreen project was considered an exemplary model of a well executed medical innovation initiative that addresses real patient needs.
MammoScreen’s rigorous data collection, realtime monitoring, and participant-centered approach holds a high standard for medical innovation. The Review Report highlighted the Consortium´s commitment to adhere to stringent data management and clinical procedures, ensuring reliable results and high quality conclusions will be obtained at the end of the project. The evaluators recognized that the successful combination of effective recruitment, data analysis and outreach reinforce the potential of MammoWave as a revolutionary tool in breast health and sets a strong precedent for future advancements in patient-centered medical device development.
